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Abstract 
Background: The association between the dopamine D2 receptor (DRD2) gene and schizophrenia has been studied 
though no conclusive outcomes have been attained. The aim of this study was to perform a systematic review and 
meta‑analysis to explore the relation between three polymorphisms of the DRD2 gene (C957T, TaqI and Ser311Cys) 
and schizophrenia.
Methods: The search was made in PubMed and EBSCO databases (up to February 2016). The systematic review 
included 34 case–control association studies (34 for C957T, 16 for TaqI and 36 for Ser311Cys). The association analysis 
comprised the allelic, additive, dominant, and recessive genetic models. The meta‑analysis was performed following 
the preferred reporting items for systematic reviews and meta‑analyses (PRISMA) statement.
Results: The meta‑analysis showed that TaqI (additive model: OR 0.57, 95% CI 0.30–1.14) and C957T (additive model: 
OR 0.75, 95% OR 0.58–0.97, recessive model: OR 0.79, 95% CI 0.64–0.98) exert a protective effect against developing 
schizophrenia. However, the sub‑analysis for the C957T variant showed that this polymorphism exhibits a risk factor 
effect on Chinese individuals (allelic model: OR 1.33, 95% CI 1.04–1.70).
Conclusion: Our meta‑analysis suggests an association of the DRD2 gene and the risk for schizophrenia, given that 
TaqI and C957T polymorphisms presented a protective effect against schizophrenia, and in the sub‑analyses the 
C957T variant increased the risk for this disorder in the Chinese population.
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Background
Schizophrenia (SZ) is a common and complex multifac-
torial psychiatric disorder characterized by a variety of 
symptoms. These symptoms involve multiple psycho-
logical domains, including inferential thinking, attention, 
social interaction, expression of emotions, and volition. 
Typically, the onset of these symptoms starts manifesting 
in adolescence or early adulthood [1, 2]. Schizophrenia is 
a highly heritable and complex multifactorial illness; its 
heterogeneity is caused by both genetic and environmen-
tal factors and their interactions [3, 4]. High genetic risk 
for schizophrenia has led to considerable research efforts 
aimed at exploring its association with a number of can-
didate genes.
Although the biological etiology of schizophrenia 
is unknown, dopamine system dysfunction has been 
widely implicated in the pathogenesis of this disorder, 
and genes involved in dopaminergic pathways are being 
studied as candidate genes [5, 6]. Particular attention 
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(DRD2). This is a transmembrane G protein-linked 
receptor which activates intracellular signaling by the 
inhibition of cAMP synthesis [7]. In humans, the DRD2 
gene is localized on chromosome 11 at the q22–q23 
locus. This gene presents multiple polymorphisms, 
about 514 (http://snpper.chip.org/bio/snpper-enter/). 
From these, we selected three functional variants [8, 
9]. The C957T (rs6277) variant constitutes a poly-
morphism with a synonymous coding C>T transi-
tion in exon 7. It has been proposed that this change 
influences the availability and affinity of the receptors 
[10–12]. Second, TaqI (rs1800497, C>T) comprises 
a substitution of an acidic amino acid for a basic one 
(Glu713Lys), and the two alleles are referred as A2 
(cytosine) and A1 (thymine), respectively. The A1 allele 
is considered the risk allele [13, 14]. Finally, the Ser-
311Cys (rs1801028, C>G) polymorphism in exon 7 can 
present two variants, in which the C allele is the normal 
allele and encodes the amino acid serine (Ser) at codon 
311, and the G allele is the risk allele and encodes a 
cysteine (Cys) [15, 16].
To date, a significant association between SZ and these 
functional DRD2 gene polymorphisms (C957T, TaqI and 
Ser311Cys) has been reported by a number of authors 
[17–19]. However, several studies have failed to replicate 
this significant association [14, 20]. At least, two meta-
analyses assessing the association between C957T, TaqI 
and Ser311Cys and schizophrenia have been performed. 
The first one was carried out by Yao et  al. [21] in 2014 
and the second by Li et  al. [22] in 2015. Given that the 
dopamine system may contribute to the risk for schizo-
phrenia, we conducted an update meta-analysis of all 
eligible published case–control studies to evaluate the 
effect of C957T, TaqI and Ser311Cys polymorphisms of 
the DRD2 gene on the overall risk for SZ. The effects of 
ethnicity were also evaluated in this study.
Methods
The search association between SZ and DRD2 gene vari-
ants was performed according to the following assess-
ments: (1) a meta-analysis of the TaqI polymorphism in 
subjects with SZ compared to healthy controls, (2) meta-
analysis of the C957T polymorphism in subjects with SZ 
compared to healthy controls, (3) meta-analysis of the 
Ser311Cys polymorphism in subjects with SZ compared 
to healthy controls, (4) meta-analysis of the TaqI poly-
morphism in schizophrenics versus healthy controls in 
the Caucasian population, (5) meta-analysis of the C957T 
polymorphism in schizophrenics versus healthy con-
trols in Caucasian and Asian populations, and a further 
analysis in Chinese and Japanese subjects, (6) meta-anal-
ysis of the Ser311Cys polymorphism in schizophren-
ics versus healthy controls by population. (7) Finally, a 
meta-regression method based on age including TaqI, 
C957T, and Ser311Cys polymorphisms was performed.
The meta-analyses were reported according to the pre-
ferred reporting items for systematic reviews and meta-
analyses (PRISMA) statement [23, 24]. The PRISMA 
checklist is included as Additional file 1.
Protocol registration
The protocol of this meta-analysis was registered in 
PROSPERO (http://www.crd.york.ac.uk/prospero/) with 
the registration number CRD42015029744.
Publication search
To identify all potentially eligible studies on DRD2 poly-
morphisms and schizophrenia risk, we performed a sys-
tematic search on PubMed and EBSCO databases that 
included all papers on the subject published up to Feb-
ruary 2016. Relevant studies were identified using the 
terms: “DRD2 AND C957T polymorphism AND schiz-
ophrenia”, “DRD2 AND rs6277 AND schizophrenia”, 
“DRD2 AND Ser311Cys polymorphism AND schizo-
phrenia”, “DRD2 AND rs1801028 AND schizophrenia”, 
“DRD2 AND TaqI polymorphism AND schizophrenia”, 
“DRD2 AND rs1800497 AND schizophrenia” “DRD 
AND rs6277”, “DRD2 AND −141CInsDel”. References 
within the retrieved articles and review articles were also 
screened. Citation lists of retrieved articles were manu-
ally examined to ensure search sensitivity.
Inclusion and exclusion criteria
Eligible studies had to meet the following criteria: (1) 
to be published in peer-reviewed journals, (2) to be 
designed as case–control studies, (3) to contain inde-
pendent data, (4) to be association studies in which the 
frequencies of three genotypes were clearly stated or 
could be calculated, (5) inclusion of SZ diagnosis in the 
patient study group, and (6) the articles had to be written 
in English. Studies were excluded when: (1) they were not 
case–control studies, (2) they were reviews, comments or 
editorial articles, (3) they provided insufficient data, and 
(4) they were repeated studies.
Data extraction
All the available data were extracted from each study by 
two researchers (Hernández-Díaz and González-Cas-
tro) working independently and in accordance with the 
inclusion criteria listed above. In case of disagreement in 
the inclusion, a third investigator was involved (Tovilla-
Zárate) to resolve the discrepancy and a final deci-
sion was reached by the majority of votes. Data such as 
authors, year of publication, location, ethnic group, num-
ber of cases and controls, age, gender, SZ diagnosis of the 
participants and genotypes were collected.
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Publication bias
The possible presence of publication bias was evaluated 
graphically by drawing funnel plots and statistically by the 
Egger’s standard regression test. In the Egger’s test p < 0.10 
was considered a statistically significant publication bias. 
The shape of the funnel plots serve as an indication of any 
obvious asymmetry for the TaqI, C957T and Ser311Cys 
variants, which was additionally supported by the Egger’s 
test. Moreover, to strengthen the analysis we evaluated 
publication bias by using the GRADE approach (Addi-
tional file 1). In addition, the 95% confidence interval (95% 
CI) of the effect size (ES) was also computed; effect size of 
0.2 was regarded as small, effect size of 0.5 was considered 
moderate and ES greater than 0.8 was taken as large.
Quality score assessment
For inclusion in the systematic review, each study was 
independently assessed by two reviewers (YHD and 
TBGC) using the Newcastle–Ottawa Assessment Scale 
(NOS) to estimate the methodological quality [25] 
(Table 1). The quality score of a given study was based on 
a score of six as cut-off point to distinguish high from low 
quality studies.
Statistical analysis
The comprehensive meta-analysis software (CMA, ver-
sion 2) was used for the statistical analyses. The results 
are presented as odds ratios (ORs) and were used to 
assess the strength of the association between TaqI, 
C957T and Ser311Cys polymorphisms of the DRD2 
gene and SZ risk. Pooled ORs with their correspond-
ing confidence intervals (95% CIs) were calculated for 
each of the models used: allelic (T vs C), additive (TT 
vs CC), dominant (TT + CT vs CC), and recessive (TT 
vs CT + TT). The estimated pooled ORs for each study 
were calculated using a random-effects model (Dersimo-
nian and Laird method), though the fixed effects model 
was also considered (Mantel–Haenszel method). Het-
erogeneity of the studies was assessed with I2 and Q test 
statistics to identify significant outcomes. The sources 
of heterogeneity were also detected by sub-group analy-
ses. Two sub-groups (Caucasian or Asian) according to 
different descents were analyzed for an ethnic-specific 
genetic comparison. Sample heterogeneity was analyzed 
with the Dersimonian and Laird’s Q test. Q test results 
were complemented with graphs to help the visualiza-
tion of those studies favoring heterogeneity. The reli-
ability of the results was assessed by sensitivity analysis 
performed for all outcomes to determine whether the 
results were driven mainly by single studies. In addition, 
we performed a meta-regression method based on age, to 
reduce the small sample size problem. We also performed 
a cumulative meta-analysis to provide a framework for 
updating the genetic effect of all studies. For the cumu-
lative meta-analysis, studies were sorted chronologically 
by year of publication. The Hardy–Weinberg equilib-
rium (HWE) was checked using a Chi square test in each 
case and control group of the included studies; values 
of p  <  0.05 were considered as showing a significant 
deviation from HWE. Finally, the strength of agreement 
between reviewers regarding study selection was evalu-
ated by Kappa statistic.
Results
Characteristics of included studies
On-line literature search supplemented with a manual 
search resulted in 285 reports comprising 86 case–con-
trol studies [1, 10–12, 14–20, 22, 26–69], which were 
included in this meta-analysis (Table  1); this consisted 
of 18,692 SZ cases and 22,032 healthy controls. Of the 
86 studies, 34 detailed the role of C957T in SZ, 36 exam-
ined the association of Ser311Cys with this disorder, and 
only 16 were available for the meta-analysis approach 
concerning the TaqI polymorphism and schizophrenia. 
In the case of TaqI, 12 studies were conducted in Cauca-
sian populations, 2 in Indian, 1 in Iranian and 1 in Turk-
ish populations, with a total of 1969 SZ cases and 1985 
healthy controls. With regard to the C957T, 18 studies 
were conducted in Caucasians, 11 in Asians, 3 studies in 
Indians, 1 in Brazil and 1 in Turkish populations; in total 
8819 SZ cases and 9965 healthy controls were included. 
Finally, for the Ser311Cys polymorphism, 18 studies were 
conducted in Asians, 15 in Caucasians and 3 in an Indian 
population with a total of 7827 SZ cases and 10,014 
healthy controls. Characteristics of the 86 studies and the 
results of the HWE test are shown in Table 1.
TaqI polymorphism and SZ
All populations
Seventeen studies were included to identify the associa-
tion between TaqI and SZ risk. Following the same pat-
tern of analysis previously established for DRD2 gene 
variants, all the genetic models: allelic (OR 0.92, 95% CI 
0.71–1.19), additive (OR 0.59, 95% CI 0.30–1.14), reces-
sive (OR 1.34, 95% CI 0.88–2.05) and dominant (OR 0.72, 
95% CI 0.49–1.06) showed heterogeneity with p  <  0.05. 
Subsequently, when we excluded the studies that favored 
the presence of the heterogeneity, we then observed the 
effect of the TaqI polymorphism in all populations using 
the additive genetic model (OR 0.57, 95% CI 0.38–0.86; p 
value of Q test: 0.32) and found a protective effect in the 
population as a whole. However, when we analyzed the 
recessive model, a risk effect was encountered (OR 1.50, 
95% CI 1.10–2.03; p value of Q test: 0.66); see Table 2). 
The Egger’s test did not yield evidence of publication 
bias (Fig. 1). To reduce the effect of the small size of the 
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Table 1 Characteristics of the studies included in this meta-analysis
Author Location Nos Number Genotypes p for HWE
Cases Controls Cases Controls Cases Controls
A1/A1 A1/A2 A2/A2 A1/A1 A1/A2 A2/A2
Taq I
 Lafuente [43] Spain 8 80 188 2 27 51 3 68 117 0.72 0.06
 Monakhov [44] Russia 8 311 364 189 104 18 238 116 10 0.51 0.48
 Lafuente [45] Spain 8 287 243 5 81 157 13 90 184 0.20 0.58
 Behravan [17] Iran 8 38 63 6 21 11 3 39 21 0.01a 0.52
 Dubertret [46] France 8 103 83 71 29 3 30 40 13 0.98 0.95
 Aslan [14] Turkey 8 99 109 2 97 0 0 106 3 0.00a 0.00a
 Comings [63] USA 4 87 69 58 27 2 59 10 0 0.56 0.37
 Sanders [65] USA 4 55 51 38 16 1 36 12 3 0.62 0.20
 Campion [79] France 5 80 80 60 19 1 58 20 2 0.70 0.86
 Nöthen [56] Germany 5 60 60 40 18 2 41 18 1 0.98 0.51
 Dollfus [80] France 6 62 61 41 19 2 11 45 5 0.91 0.00a
 Jonsson [66] Sweden 6 104 67 70 30 4 45 18 4 0.74 0.24
 Dubertret [52] France 7 50 50 36 13 1 26 21 3 0.88 0.63
 Parsons [81] Spain 8 119 165 92 24 3 93 68 4 0.39 0.04a
 Vijayan [1] India 8 212 194 102 93 17 88 77 29 0.62 0.08
 Srivastava [61] India 8 222 138 123 93 6 21 96 21 0.02a 0.00a
Author Location Nos Number Genotypes p for HWE
Cases Controls Cases Controls Cases Controls
CC CT17 TT CC 107CT TT
C957T
 Jonsson [66] Sweden 7 173 236 160 12 1 232 4 0 0.23 1.00
 Lawford [11] Australia 6 154 148 48 75 31 27 70 51 0.87 0.73
 Hanninen [10] Finland 7 188 384 59 92 37 104 176 104 0.91 0.102
 Kukreti [47] India 7 101 145 41 38 22 48 64 33 0.03a 0.23
 Hoenicka [19] Spain 7 131 364 30 61 40 46 174 144 0.48 0.65
 Mo [48] China 8 174 127 61 96 17 29 69 29 0.02a 0.37
 Luo [49] China 6 466 388 409 55 2 351 37 0 0.70 0.98
 Monakhov [44] Russia 8 311 364 99 152 60 78 183 103 0.90 0.91
 Gupta [41] India 8 254 225 104 112 38 76 120 29 0.41 0.09
 Betcheva [12] Bulgaria 8 255 556 58 128 66 192 253 111 0.89 0.09
 Dubertret [46] France 7 144 142 104 37 3 120 21 1 0.92 0.94
 Fan [20] China 8 421 403 366 52 3 368 34 1 0.43 0.55
 Tsutsumi [42] Japan 9 407 384 367 38 1 341 43 2 0.98 0.64
 Arinami [27] Japan 6 260 312 190 66 4 193 102 17 0.79 0.50
 Li [82] England 7 151 145 112 39 0 118 26 1 0.01a 0.72
 Ohara [32] Japan 7 170 121 136 34 0 84 36 1 0.37 0.30
 Stöber [64] Germany 7 260 290 207 50 3 236 53 1 0.99 0.21
 Breen (1) [83] England 7 378 292 293 78 7 227 61 4 0.47 0.96
 Breen (2) Scotland 7 151 145 115 33 3 118 26 1 0.71 0.72
 Inada [84] Japan 7 234 94 156 72 6 51 40 3 0.65 0.26
 Tallerico [85] Canada 7 50 51 40 10 0 43 7 1 0.29 0.36
 Hori [39] Japan 7 241 201 162 71 8 142 54 5 0.94 0.96
 Himei [40] Japan 7 190 103 118 69 3 71 27 5 0.06 0.30
 Dubertret [52] France 8 103 83 83 19 1 43 33 7 0.93 0.79
 Kapman [86] Finland 7 93 94 86 7 0 88 6 0 0.60 0.65
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sample in the analyses, we performed a meta-regression 
method based on age for the whole population. This anal-
ysis revealed a point estimate slope of −0.05365 and p 
value of 0.01686 (Fig. 2).
Caucasian population
Given that previous studies have reported a positive asso-
ciation between TaqI and SZ risk in Caucasians [46], we 
decided to conduct a meta-analysis on the Caucasian 
population. This sub-group analysis by ethnicity included 
seven studies which showed no evidence of any associa-
tion between TaqI and SZ in Caucasian populations. The 
results for the different genetic models were: allelic (OR 
0.86, 95% CI 0.71–1.05; p value of Q test: 0.55), recessive 
(OR 0.90, 95% CI 0.69–1.18; p value of Q test: 0.40) and 
dominant (OR 0.89, 95% CI 0.71–1.11; p value of Q test: 
Table 1 continued
Author Location Nos Number Genotypes p for HWE
Cases Controls Cases Controls Cases Controls
CC CT17 TT CC 107CT TT
 Parsons [81] Spain 8 108 153 88 20 0 135 18 0 0.59 0.28
 Lafuente [45] Spain 8 243 291 208 33 2 235 54 2 0.63 0.75
 Luu [67] China 8 211 201 165 44 2 163 34 4 0.60 0.24
 Sanders [57] Europe 8 1870 2002 1495 354 21 1643 341 18 0.99 0.94
 Cordeiro [68] Brazil 8 229 733 183 38 8 498 206 29 0.00a 0.20
 Srivastava [61] India 8 233 224 161 65 7 172 48 4 0.81 0.75
 Kurt [87] Turkey 8 73 60 45 26 2 34 25 1 0.71 0.26
 Saiz [88] Spain 8 272 404 181 76 15 301 98 5 0.08 0.51
 Xiao [69] China 8 120 100 96 22 2 68 28 4 0.62 0.51
a Significant p value
Table 2 Analysis of the association studies between the DRD2 gene TaqI polymorphism and SZ in all populations and in a 
Caucasian sub-group
Italic values denote significant value, p < 0.05






 Allelic With heterogeneity 0.92 (0.71–1.19) 0.89 (0.80–0.99) <0.00
Without heterogeneity 0.92 (0.79–1.07) 0.92 (0.81–1.05) 0.256
 Additive With heterogeneity 0.59 (0.30–1.14) 0.51 (0.37–0.71) <0.00
Without heterogeneity 0.57 (0.38–0.86) 0.57 (0.39–0.81) 0.326
 Recessive With heterogeneity 1.34 (0.88–2.05) 1.17 (0.95–1.44) <0.00
Without heterogeneity 1.50 (1.10–2.03) 1.50 (1.10–2.03) 0.664
 Dominant With heterogeneity 0.72 (0.49–1.06) 0.72 (0.62–0.84) <0.00
Without heterogeneity 0.85 (0.72–1.01) 0.85 (0.72–1.01) 0.586
Caucasian population
 Allelic With heterogeneity 0.88 (0.66–1.18) 0.86 (0.77–0.96) <0.00
Without heterogeneity 0.86 (0.71–1.05) 0.86 (0.71–1.05) 0.551
 Additive With heterogeneity
Without heterogeneity 0.60 (0.36–0.99) 0.59 (0.39–0.91) 0.263
 Recessive With heterogeneity
Without heterogeneity 0.90 (0.69–1.18) 0.90 (0.71–1.15) 0.403
 Dominant With heterogeneity 0.76 (0.50–1.14) 0.77 (0.64–0.93) <0.00
Without heterogeneity 0.89 (0.71–1.11) 0.89 (0.72–1.10) 0.397
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0.39). However, in the additive model we observed a pro-
tective effect of TaqI on schizophrenia (OR 0.60, 95% CI 
0.36–0.99; p value of Q test: 0.26) (Fig. 3).
C957T polymorphism and schizophrenia
All populations
We performed an analysis in the population as a whole 
to explore the probable risk role of the C957T polymor-
phism in schizophrenia. Initially, we conducted a meta-
analysis with the four genetic models proposed: allelic 
(OR 0.92, 95% CI 0.81–1.05), additive (OR 0.77, 95% CI 
0.57–1.05), recessive (OR 0.84, 95% CI 0.66–1.06) and 
dominant (OR 0.91, 95% CI 0.78–1.05), in which p of Q 
test <0.05 indicated heterogeneity. No statistical associa-
tion was found between the C957T polymorphism and 
schizophrenia. However, when we discarded the studies 
favoring heterogeneity, we obtained the following out-
comes of statistical association for the models: additive 
(OR 0.75, 95% CI 0.58–0.97; p value of Q test: 0.15) and 
recessive (OR 0.79; 95% CI 0.64–0.98; p value of Q test: 
0.21) (Table  3). In addition, the Egger’s test revealed no 
evidence of publication bias (Fig. 4). With regard to the 
meta-regression based on age, the slope was 0.00849 and 
the p value 0.38756 (Fig. 2).
Caucasian population
We performed a stratified analysis by ethnicity to meas-
ure SZ risk by populations. With regard to Caucasians, 
the first outcomes with a p of Q test <0.05 showed evi-
dence of heterogeneity in the allelic (OR 0.98, 95% CI 
0.81–1.18), additive (OR 0.85, 95% CI 0.54–1.34), reces-
sive (OR 0.89, 95% CI 0.65–1.23) and dominant (OR 0.98, 
95% CI 0.79–1.21) models. Subsequently, when hetero-
geneity was discarded, the outcome presented a positive 
association with schizophrenia in the allelic model (OR 
0.73, 95% CI 0.60–0.89; p value of Q test: 0.44). However, 
a slight possibility of an association in the additive (OR 
0.80, 95% CI 0.66–0.97; p value of Q test <0.00) and reces-
sive (OR 0.83, 95% CI 0.71–0.98; p value of Q test <0.00) 
models could be suggested. But since these findings were 
in the presence of heterogeneity and using the fixed 
effects model, we did not consider them for the analysis. 
For all the analyses in Caucasians, the p value of the Egg-
er’s test suggested the non-existence of publication bias 
(Fig. 5).
Asian population
Finally, for the C957T polymorphism in the Asian 
population we followed the same pattern of analysis 
Fig. 1 a Flow‑chart design to show the inclusion of studies in this meta‑analysis. b Forest plots of the allelic model for TaqI. c Forest plots of the 
dominant model for TaqI. d Begg’s funnel plot analysis of publication bias in the allelic model for TaqI
Page 7 of 14González‑Castro et al. Behav Brain Funct  (2016) 12:29 
as in the previous sub-section. In the initial analysis 
the outcomes exhibited the presence of heterogene-
ity (p < 0.05) in the allelic (OR 0.84, 95% CI 0.66–1.07) 
and dominant models (OR 0.84, 95% CI 0.64–1.10). 
After we excluded the studies that favored heteroge-
neity, the results evidenced an association between 
the C957T polymorphism and SZ in the four models: 
allelic (OR 0.66, 95% CI 0.52–0.83; p value of Q test: 
0.72), additive (OR 0.49, 95% CI 0.28–0.86; p value of 
Q test: 0.20), recessive (OR 0.52, 95% CI 0.32–0.83; p 
value of Q test: 0.33) and dominant (OR 0.61, 95% CI 
0.50–0.74; p value of Q test: 0.061), using the random 
effects method. However, we want to emphasize that 
the outcomes showed the same protective association 
between C957T and SZ in the all models when we used 
the fixed effects model.
C957T polymorphism in Chinese and Japanese populations
In order to perform a more comprehensive and com-
parative meta-analysis we conducted two more sub-
analyses, but only for the subjects born in Japan and in 
China. These sub-analyses helped to compare our find-
ings with previous published met-analyses. Initially, we 
selected the studies that explored the role of C957T in 
Japanese schizophrenics and found a relation to SZ in the 
four models without heterogeneity, viz.: allelic (OR 0.69, 
95% CI 0.57–0.85; p value of Q test: 0.11), additive (OR 
0.51, 95% CI 0.27–0.95; p value of Q test: 0.24), recessive 
(OR 0.54, 95% CI 0.29–0.99; p value of Q test: 0.27) and 
dominant (OR 0.58, 95% CI 0.45–0.76; p value of Q test: 
0.98), but all the results were for the fixed effects model. 
Nevertheless, when we used the random effects method 
we encountered the same pattern only in the allelic (OR 
Fig. 2 Meta‑regression method based on age in the population as a whole. a TaqI polymorphism and b C957T polymorphism
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0.71, 95% CI 0.53–0.94) and dominant (OR 0.58, 95% CI 
0.45–0.76) models. With regard to the Chinese popula-
tion, we found a similar association to that of the previ-
ous sub-analysis. Interestingly, we found a risk effect in 
the allelic (OR 1.33, 95% CI 1.04–1.70; p value of Q test: 
0.50) and dominant (OR 1.36, 95% CI 1.04–1.77; p value 
of Q test: 0.69) models, without heterogeneity using the 
random effects method (Table 4).
Ser311Cys polymorphism and SZ
For this polymorphism the meta-analysis was performed 
for the overall population. The outcomes in Caucasian 
and Asian populations were similar to those found for 
the previous variants. Since the present work showed the 
same results as in previous studies [21], we will not dis-
cuss this polymorphism in the present work. However, 
we present the details in Additional file 2.
Sensitivity analysis
In addition, a sensitivity analysis was carried out in 
which one study at a time was excluded to determine 
whether a specific study was favoring a marked hetero-
geneity. Nevertheless, the presence of heterogeneity was 
not explained by just one study. Furthermore, to meas-
ure the effects over time on the studies, we performed a 
cumulative meta-analysis, in which individual data sets 
were ordered chronologically (Additional file 3).
Discussion
Schizophrenia is a complex genetic disorder manifest-
ing combined environmental and genetic factors. Several 
studies have suggested that genetic variants of the DRD2 
gene play a role in SZ etiology [70, 71]. To assess the rela-
tionship between the DRD2 genetic variants and the risk 
to develop schizophrenia, we conducted a meta-analysis 
of three DRD2 polymorphisms: TaqI, C957T and Ser-
311Cys. The meta-analysis approach is a powerful tool 
to summarize contradicting results from different studies 
and has been used to analyze the role of various genes in 
schizophrenia [54, 72, 73].
First, we performed the analysis of the TaqI polymor-
phism to assess the role of this genetic variant in schiz-
ophrenia. There was a protective effect in the additive 
model in the population as a whole and in Caucasians. 
Also, we found a risk effect when using the recessive 
model in the combined results of the analysis for all 
populations. However, various studies have reported 
that TaqI polymorphism does not play an important role 
in the psychopathological symptoms of schizophrenia, 
whereas other researches agree with our results [21, 22, 
63, 66]. One of the reasons for this discrepancy could 
Fig. 3 a Forest plots of the allelic model for TaqI in Caucasians. b Begg’s funnel plot analysis of publication bias of the allelic model for TaqI in 
Caucasians. c Forest plots of the dominant model for TaqI in Caucasians. d Begg’s funnel plot analysis of publication bias in the dominant model for 
TaqI in Caucasians
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be the relative small size of the sample, which limits 
the statistical power for the detection of a relationship 
between the TaqI polymorphism and schizophrenia [72]; 
more studies are needed to further validate these results. 
Another explanation is the environmental exposure that 
could trigger the expression of a gene, and this in turn 
could modify other genes which may then interact with 
DRD2 and increase the risk to present the disease. In 
spite of the contrasting outcomes published, the role of 
TaqI has been more related to substance abuse, since the 
less frequent allele (A1 allele) has been associated with 
some psychiatric disorders such as alcoholism and sub-
stance abuse [74, 75]. On the other hand, previous stud-
ies have demonstrated that subjects with one or two A1 
alleles of the DRD2 polymorphism at the Taq1 A locus 
present lower DRD2 density than those with no A1 allele 
[76]. Also, other studies have shown that female patients 
with the A1 allele exhibit greater prolactin response to 
nemonapride, a selective antagonist for D2-like dopa-
mine receptors in schizophrenic patients [77]. Due to 
this association between TaqI and schizophrenia, the A1 
allele has been suggested to diminish dopaminergic activ-
ity in the central nervous system [78].
For the C957T polymorphism, the comparisons 
performed in our study showed a significant posi-
tive association between this polymorphism and SZ 
in the overall population and in Caucasian and Asian 
sub-groups. In this sense, we recognize the existence 
of two previous meta-analyses [21, 22], in which many 
differences are observed: first, we identified a protec-
tive effect of the T allele of C957T using the additive 
and recessive models when analyzing the population as 
a whole, as well as when using the recessive model in 
Caucasians and the four genetic models in Asians. In 
contrast, Yao et al. did not observe any association. The 
differences could be due to the size of the samples. Our 
Table 3 Analysis of association studies between the DRD2 gene C957T polymorphism and schizophrenia by populations
Italic values denote significant value, p < 0.05






 Allelic With heterogeneity 0.92 (0.81–1.05) 0.93 (0.87–0.98) <0.00
Without heterogeneity 1.03 (0.93–1.15) 1.03 (0.93–1.15) 0.595
 Additive With heterogeneity 0.77 (0.57–1.05) 0.76 (0.65–0.89) <0.00
Without heterogeneity 0.75 (0.58–0.97) 0.74 (0.61–0.91) 0.151
 Recessive With heterogeneity 0.84 (0.66–1.06) 0.82 (0.72–0.94) <0.00
Without heterogeneity 0.79 (0.64–0.98) 0.78 (0.66–0.92) 0.211
 Dominant With heterogeneity 0.91 (0.78–1.05) 0.94 (0.88–1.01) <0.00
Without heterogeneity 0.89 (0.77–1.03) 0.89 (0.78–1.02) 0.308
Caucasian population
 Allelic With heterogeneity 0.98 (0.81–1.18) 0.98 (0.91–1.05) <0.00
Without heterogeneity 1.03 (0.88–1.21) 1.00 (0.87–1.14) 0.252
 Additive With heterogeneity 0.85 (0.54–1.34) 0.80 (0.66–0.97) <0.00
Without heterogeneity 0.94 (0.63–1.40) 0.90 (0.63–1.27) 0.354
 Recessive With heterogeneity 0.89 (0.65–1.23) 0.83 (0.71–0.98) <0.00
Without heterogeneity 0.73 (0.60–0.89) 0.73 (0.60–0.89) 0.440
 Dominant With heterogeneity 0.98 (0.79–1.21) 1.03 (0.93–1.13) <0.00
Without heterogeneity 1.04 (0.89–1.21) 1.03 (0.89–1.20) 0.400
Asian population
 Allelic With heterogeneity 0.84 (0.66–1.07) 0.82 (0.73–0.93) <0.00
Without heterogeneity 0.66 (0.52–0.83) 0.66 (0.52–0.83) 0.725
 Additive With heterogeneity
Without heterogeneity 0.49 (0.28–0.86) 0.45 (0.29–0.70) 0.206
 Recessive With heterogeneity
Without heterogeneity 0.52 (0.32–0.83) 0.49 (0.32–0.75) 0.330
 Dominant With heterogeneity 0.84 (0.64–1.10) 0.85 (0.73–0.99) <0.00
Without heterogeneity 0.61 (0.50–0.74) 0.61 (0.50–0.74) 0.864
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Fig. 4 a Forest plots of the allelic model for C957T. b Begg’s funnel plot analysis of publication bias in the allelic model for C957T. c Forest plots of 
the dominant model for C957T. d Begg’s funnel plot analysis of publication bias in the dominant model for C957T
Fig. 5 a Forest plots of the allelic model for C957T in Caucasians. b Begg’s funnel plot analysis of publication bias in the allelic model for C957T in 
Caucasians. c Forest plots of the dominant model for C957T in Caucasians. d Begg’s funnel plot analysis of publication bias in the dominant model 
for C957T in Caucasians
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present study used 8819 SZ patients and 9965 healthy 
controls compared with 6075 SZ and 6643 controls 
of the previous meta-analysis by Yao et  al. [21]. We 
included 2792 cases and 3322 controls more. In the 
Asian population a protective effect was found in all 
the models we used. As a consequence, we decided to 
perform an analysis by Asiatic subpopulations. There-
fore, we divided the Asian population into Chinese and 
Japanese samples. In these sub-analyses we encoun-
tered unexpected results: the Chinese population 
showed an increased risk, whereas the Japanese popu-
lation showed a protective association. This is clear an 
“allele paradox” between populations that may reflect 
the difference in the distribution of allele frequencies 
across the geographical localization. Our results draw 
attention to the influence of other factors such as the 
environment, which could be acting with ethnicity in 
this genetic association.
There are several limitations in this study. First, the 
sample size for some sub-group analyses was limited; 
therefore, more studies with larger samples should be 
included to enhance the reliability and stability of the 
meta-analysis. Second, a language bias may be pre-
sent given that only studies published in English were 
included. Third, due to the limitation of the data, we did 
not stratify according to other potential factors which 
may enhance the risk for the development of SZ, such as 
gender, age of onset and clinical manifestations.
Conclusions
The meta-analysis indicated that TaqI and C957T poly-
morphisms show a protective effect against SZ. In the 
sub-analysis of the C957T polymorphism we observed 
that this variant may contribute to the occurrence of 
schizophrenia in Chinese subjects, so the influence of 
ethnicity could be important in modifying the role of 
this polymorphism in SZ. Given the limitations of the 
studies included in the meta-analysis, future studies 
with larger samples and prospective designs are needed 
to fully understand the relationship between these pol-
ymorphisms and SZ. However, this meta-analysis still 
provides new insights into the role of the DRD2 gene in 
SZ risk.
Additional files
Additional file 1. Grades quality assessment and PRISMA check list.
Additional file 2. Association of the C957T polymorphism and 
schizophrenia.
Additional file 3. Sensitivity analysis and cumulative meta‑analysis.
Table 4 Analysis of association studies between the DRD2 C957T polymorphism and schizophrenia in China and Japan
Italic values denote significant value, p < 0.05






 Allelic With heterogeneity 0.79 (0.58–1.07) 0.78 (0.66–0.93) 0.017
Without heterogeneity 0.71 (0.53–0.94) 0.69 (0.57–0.85) 0.112
 Additive With heterogeneity
Without heterogeneity 0.50 (0.24–1.07) 0.51 (0.27–0.95) 0.243
 Recessive With heterogeneity
Without heterogeneity 0.53 (0.26–1.08) 0.54 (0.29–0.99) 0.279
 Dominant With heterogeneity 0.79 (0.55–1.14) 0.78 (0.64–0.96) 0.011
Without heterogeneity 0.58 (0.45–0.76) 0.58 (0.45–0.76) 0.988
China
 Allelic With heterogeneity 0.95 (0.62–1.45) 0.92 (0.77–1.11) <0.00
Without heterogeneity 1.33 (1.04–1.70) 1.33 (1.04–1.70) 0.507
 Additive With heterogeneity
Without heterogeneity 0.55 (0.21–1.39) 0.40 (0.22–0.73) 0.173
 Recessive With heterogeneity
Without heterogeneity 0.54 (0.25–1.15) 0.46 (0.26–0.79) 0.283
 Dominant With heterogeneity 0.96 (0.62–1.48) 1.02 (0.82–1.28) <0.00
Without heterogeneity 1.36 (1.04–1.77) 1.36 (1.04–1.77) 0.697
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